Israel Englander I Teos Therapeutics, Inc. Transaction History

Millennium Management LLC

$199 Billion
Q3 2024

A detailed history of Israel Englander (Millennium Management LLC) transactions in I Teos Therapeutics, Inc. stock. As of the latest transaction made, Millennium Management LLC holds 37,073 shares of ITOS stock, worth $303,627. This represents 0.0% of its overall portfolio holdings.

Number of Shares

37,073

Previous 241,305 84.64%

Holding current value

$303,627

Previous $3.58 Million 89.44%

% of portfolio

0.0%

Previous 0.0%

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 14, 2024	SELL	$10.09 - $17.97 $2.06 Million - $3.67 Million	-204,232 Reduced 84.64%	37,073 $378,000
Q2 2024 Aug 14, 2024	SELL	$10.33 - $18.09 $6.63 Million - $11.6 Million	-641,676 Reduced 72.67%	241,305 $3.58 Million
Q1 2024 May 15, 2024	SELL	$9.89 - $13.64 $834,923 - $1.15 Million	-84,421 Reduced 8.73%	882,981 $12 Million
Q4 2023 Feb 14, 2024	BUY	$8.57 - $11.06 $1.21 Million - $1.56 Million	141,300 Added 17.1%	967,402 $10.6 Million
Q2 2023 Aug 14, 2023	BUY	$12.93 - $18.05 $3.85 Million - $5.38 Million	297,830 Added 56.38%	826,102 $10.9 Million
Q1 2023 May 15, 2023	SELL	$13.02 - $22.62 $4.51 Million - $7.83 Million	-346,208 Reduced 39.59%	528,272 $7.19 Million
Q4 2022 Feb 14, 2023	BUY	$17.77 - $21.6 $2.42 Million - $2.94 Million	136,124 Added 18.44%	874,480 $17.1 Million
Q3 2022 Nov 14, 2022	BUY	$18.6 - $27.25 $7.69 Million - $11.3 Million	413,659 Added 127.4%	738,356 $14.1 Million

Others Institutions Holding ITOS

# of Institutions

166

Shares Held

36.6M

Call Options Held

1.95M

Put Options Held

374K

View Full List

About iTeos Therapeutics, Inc.

Ticker ITOS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 35,575,300
Market Cap $291M
Description
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or ...

More about ITOS

Track Israel Englander's Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.

Account